15.03.2015 Views

April 2012 Drug Information Update - Pharmacy Benefits ...

April 2012 Drug Information Update - Pharmacy Benefits ...

April 2012 Drug Information Update - Pharmacy Benefits ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

5 mg single dose vial, package of 1 (NDC 55390-0251-01)<br />

20 mg single dose vial, package of 1 (NDC 55390-0252-01)<br />

40 mg single dose vial, package of 1 (NDC 55390-0253-01)<br />

5 mg Novaplus single dose vial, package of 1 (NDC 55390-0451-01)<br />

20 mg Novaplus single dose vial, package of 1 (NDC 55390-0452-01)<br />

40 mg Novaplus single dose vial, package of 1 (NDC 55390-0453-01)<br />

Mitomycin Powder for Injection (Mannitol Formulation), Accord<br />

5 mg single dose vial (NDC 16729-0115-05)<br />

20 mg single dose vial (NDC 16729-0108-11)<br />

Reason for the Shortage<br />

• Ben Venue voluntarily suspended all manufacturing and distribution in mid-November, 2011.<br />

Product will become available in stages as production resumes.<br />

• Bedford Laboratories has multiple products affected by this suspension of manufacturing.<br />

Availability of all products, including those not manufactured at Ben Venue, is updated as<br />

information changes on the Bedford Laboratories website.<br />

• Accord states the reason for the shortage is increased demand.<br />

Article link: http://www.ashp.org/<strong>Drug</strong>Shortages/Current/Bulletin.aspx?id=433<br />

Source: www.ashp.org<br />

Epinephrine Injection<br />

March 27, <strong>2012</strong><br />

Products Affected - Description<br />

Epinephrine injection, 1 mg/mL, American Regent<br />

1 mL ampule, sulfite-free, package of 25 (NDC 00517-1071-25)<br />

Reason for the Shortage<br />

• American Regent had temporarily suspended manufacture of most drug products in <strong>April</strong>, 2011.<br />

• American Regent resumed manufacturing in Shirley, New York in early-May, 2011.<br />

Article link: http://www.ashp.org/<strong>Drug</strong>Shortages/Current/Bulletin.aspx?id=685<br />

Source: www.ashp.org<br />

Bupivacaine with epinephrine injection<br />

March 27, <strong>2012</strong><br />

Products Affected - Description<br />

Bupivacaine 0.25% with epinephrine<br />

Bupivacaine 0.25% with epinephrine 1:200,000 injection, Hospira<br />

10 mL vial, preservative-free (NDC 00409-9042-01)<br />

50 mL vial, multi-dose (NDC 00409-9043-01)<br />

30 mL vial, preservative-free (NDC 00409-9042-17)<br />

Marcaine 0.25% (with epinephrine 1:200,000) injection, Hospira<br />

10 mL vial, preservative-free (NDC 00409-1746-10)<br />

30 mL vial, preservative-free (NDC 00409-1746-30)<br />

50 mL vial, multi-dose (NDC 00409-1752-50)<br />

Sensorcaine 0.25% (with epinephrine 1:200,000), APP<br />

10 mL vial, preservative-free (NDC 63323-0468-17)<br />

30 mL vial, preservative-free (NDC 63323-0468-37)<br />

50 mL vial, multi-dose (NDC 63323-0461-57)<br />

Bupivacaine 0.5% with epinephrine<br />

Bupivacaine 0.5% with epinephrine 1:200,000 injection, Hospira<br />

63

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!